
Quest Diagnostics statistics
$259.60−0.02%Close 13 Nov 2026 · Market value $28.70B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Quest Diagnostics is valued at $28.70B on its latest close. Its price is 25.4 times its earnings.
| Market value | $28.70B |
|---|
| Enterprise value | $34.45B |
|---|
| Price / earnings | 25.42 |
|---|
| Price / sales | 2.42 |
|---|
| Price / book | 3.76 |
|---|
| EV / EBITDA | 14.93 |
|---|
| EV / sales | 2.91 |
|---|
| Price / free cash flow | 20.87 |
|---|
| Price / free cash flow, own 5-year average | 15.92 |
|---|
| EV / EBIT | 19.84 |
|---|
| EV / free cash flow | 24.87 |
|---|
| Free cash flow yield | 4.8% |
|---|
| Dividend yield | 1.3% |
|---|
Share price
| Latest close | $259.60 |
|---|
| Day's change | −0.0% |
|---|
| 52-week high | $262.00 |
|---|
| 52-week low | $171.18 |
|---|
| From 52-week high | −0.9% |
|---|
| Return · 1 month | +10.5% |
|---|
| Return · 3 months | +7.6% |
|---|
| Return · year to date | +49.6% |
|---|
| Return · 1 year | +38.9% |
|---|
| Beta · 1 year against the S&P 500 | −0.06 |
|---|
| 50-day average | $241.30 |
|---|
| 200-day average | $215.70 |
|---|
| RSI 14 | 69.1 |
|---|
| Average volume · 20 sessions | 968K |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 33.2% |
|---|
| Operating margin | 14.1% |
|---|
| Net margin | 9.0% |
|---|
| Free cash flow margin | 12.3% |
|---|
| Return on equity | 14.2% |
|---|
| Return on assets | 7.3% |
|---|
| Return on invested capital | 8.2% |
|---|
| Return on invested capital, 5-year average | 10.2% |
|---|
| Return on capital employed | 11.1% |
|---|
| Stock-based compensation / revenue | 0.8% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $420.0M |
|---|
| Total debt | $6.38B |
|---|
| Net debt | $5.96B |
|---|
| Current ratio | 1.04 |
|---|
| Quick ratio | 1.37 |
|---|
| Debt / equity | 0.89 |
|---|
| Net debt / EBITDA | 2.80 |
|---|
| Interest coverage | 5.62 |
|---|
Growth
| Revenue, latest quarter on a year | +10.0% |
|---|
| Revenue, twelve months on a year | +9.1% |
|---|
| EPS, latest quarter on a year | +28.7% |
|---|
| EPS, twelve months on a year | +17.6% |
|---|
| Revenue, 5-year compound | +3.2% |
|---|
| Revenue, 10-year compound | +3.9% |
|---|
| Net income, 5-year compound | −7.1% |
|---|
| Free cash flow, 5-year compound | −3.1% |
|---|
| EPS, 5-year compound | −3.6% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 113M |
|---|
| Shares outstanding, 5-year compound | −3.6% |
|---|
| Net share repurchases | $371.0M |
|---|
| Dividend payout | 35.6% |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $314.0M |
|---|
| Effective tax rate | 23.8% |
|---|
DGX in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.